Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Mary E. Charlson, Peter Pompei, Kathy L. Aleš et al. · Journal of Chronic Diseases · 1987 · 49.9K citations

Public Health, Biostatistics, Clinical Classification Systems +15

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair et al. · New England Journal of Medicine · 2000 · 3K citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

Reva C. Lawrence, Charles G. Helmick, Frank C. Arnett et al. · Arthritis & Rheumatism · 1998 · 2.7K citations

Medicine, Internal Medicine, Disease Surveillance +16

An Introduction to Generalized Linear Models.

Potter C. Chang, Annette J. Dobson · Journal of the American Statistical Association · 1991 · 2.6K citations

Business, Biostatistics, Econometrics +9

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +15